Evidence map›Paper›PMID 31171887›Full record

SynthesisWorld journal of gastroenterology2019

Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency.

Peter Layer, Nataliya Kashirskaya, Natalya Gubergrits

Registry-linked trialOpen access · hybridAbstract readEvaluation StudySystematic Review
In one paragraph

Synthesis in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05480241 (Impact of Exocrine Pancreatic Insufficiency Associated With Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy on Gut Microbiota, Immunological Changes and Quality of Life), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05480241 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Impact of Exocrine Pancreatic Insufficiency Associated With Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy on Gut Microbiota, Immunological Changes and Quality of Life

TypeinterventionalSponsorUnidade Local de Saúde de Coimbra, EPERan2022 to 2024Enrolled84ConditionsAcute Pancreatitis, Exocrine Pancreatic Insufficiency, Gut Microbiota, ImmunologyArmsPancreatic Enzyme Replacement Therapy, Placebo
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Clinical Practice Update on the Evaluation, Diagnosis, and Management of Pancreatic Exocrine Insufficiency: Expert Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Review
  5. Article
  6. Exocrine pancreatic insufficiency and pancreatic enzyme supplementation after gastric resection-A scoping review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Peter LayerDepartment of Internal Medicine, Israelitic Hospital, Hamburg 22297, Germany. p.layer@ik-h.de.
Nataliya KashirskayaDepartment of Genetic Epidemiology (Cystic Fibrosis group), Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow 115522, Russia.
Natalya GubergritsDepartment of Internal Medicine, Donetsk National Medical University, Lyman 83001, Ukraine.
Donetsk National Medical University · UAIsraelitisches Krankenhaus · DEResearch Centre for Medical Genetics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to analyze the current evidence for the use of pancreatic enzyme replacement therapy (PERT) in affecting survival and quality of life in patients with pancreatic exocrine insufficiency (PEI). Systematic searches of the literature were performed using the PubMed database. Articles were selected for inclusion if they reported findings from trials assessing the effects of PERT on quality of life, survival, malabsorption, growth parameters (such as height, body weight and body mass index), or gastrointestinal symptoms (such as abdominal pain, stool consistency and flatulence). PERT improved PEI-related malabsorption and weight maintenance in patients with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states. In patients with chronic pancreatitis, PERT improved PEI-related symptoms and quality of life measures. Several small retrospective studies have also suggested that PERT may have a positive impact on survival, but long-term studies assessing this effect were not identified. PERT is effective for treating malnutrition and supporting weight maintenance, and it is associated with improved quality of life and possibly with enhanced survival in patients with PEI. However, there is evidence that not all patients with PEI receive adequate PERT. Future work should aim to assess the long-term effects of PERT on the survival of patients with PEI.

Indexed as

Quality of LifeEnzyme Replacement TherapyEvidence-Based MedicineExocrine Pancreatic InsufficiencyHumansMalnutritionPancreasTime FactorsTreatment OutcomeChronic pancreatitisCystic fibrosisMalabsorptionPancreatic cancerPancreatic enzyme replacement therapyPancreatic exocrine insufficiencyPost-surgical statesQuality of lifeSurvival

Identifiers

PMID31171887
PMCPMC6543241
OpenAlexW2947916602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.